“In exchange for the grant of exclusive worldwide rights, once Alterity generates commercialization revenue, UniQuest is entitled to receive certain payments including milestone and royalty payments commensurate with academic licenses. Alterity intends to direct new resources to the project with no impact on its lead commercialisation program for ATH434, which is advancing to Phase 2 in Multiple System Atrophy, a Parkinsonian disorder with no approved therapy.”
Ann: New commercial opportunity for PBT2, page-8
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $17.30K | 3.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 42714645 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22897179 | 17 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.5¢ | 1250891 | ||
| Last updated 15.59pm 13/05/2024 ? | |||||
| ATH (ASX) Chart |